BCL2 and breast cancer: The possible TAMs-modulated drug resistance mechanism involved may be associated with elevation of bcl-2 gene expression and up-regulation of STAT3 signaling in tumor cells, forming IL-10/STAT3/bcl-2 signaling axis accounting for chemoresistance of breast cancer [75].